Results of treating severe acute XXXX with gabexate is associated with neutrophil apoptosis activity.

@entity1 @entity650 @entity788 @entity5722 @entity1454 @entity881 @entity687
BACKGROUND/AIMS: A delay in polymorphonuclear neutrophil apoptosis has been implicated in the pathogenesis of systemic inflammatory reactions in certain conditions. @entity5722 has been proven effective in the treatment of severe acute @entity788 with @entity881 . In this study, we attempted to answer the questions of whether neutrophil apoptosis is associated with the conditions of various major organs in @entity1 with severe acute @entity788 and receiving gabexate. METHODOLOGY: A total of 45 @entity1 were included in this study. We divide the @entity1 into two groups. Group A included @entity1 with > or = 2 complications after one-week treatment (n = 31), and Group B included @entity1 with < 2 complications after one-week treatment (n = 14). Serum @entity650 and @entity687 was detected at day 1, 3, and 7 of treatment using enzyme-linked immunosorbent assay kits. The neutrophil @entity1454 expression and apoptosis activity were evaluated flowcytometrically at day 1, 3, and 7 of treatment. RESULTS: At day 7 of treatment, @entity650 levels were significantly higher in Group B while @entity687 levels were not different. The neutrophil @entity1454 expression was significantly higher and delayed ex vivo apoptosis was significantly lower in the group B than that of group A at day 7 of treatment. CONCLUSIONS: In @entity1 of severe acute @entity788 with @entity881 and receiving @entity5722 treatment, neutrophil apoptosis is associated with the severity of @entity881 .
